New pill targets Hard-to-Treat cancers with rare TP53 mutation

NCT ID NCT07060989

Recruiting now Disease control Sponsor: Nutshell Therapeutics (Shanghai) Co., LTD. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who have already tried other cancer treatments will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NTS071 (oral drug)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have a specific TP53 mutation.
What could go wrong: This is an early-phase trial (Phase 1/2a) with a small number of participants, so the drug may not prove effective or safe enough for wider use. Side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Next Oncology
RECRUITING

San Antonio, Texas, 78201, United States
Shanghai
RECRUITING

Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.